Such one combination with an inhibitor of PDGF, VEGF, and bFGF receptors has been evaluated in cancer patients, with a disease control in 18/30 evaluable patients in which one partial response in NSCLC [36]. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.